Mark Elliott Boulding, Executive VP AND CLO at PTC THERAPEUTICS, INC. (PTCT), sold 2,812 shares at $72.08 ($203K) on 2026-05-15, disclosed to the SEC on 2026-05-19.
Scheduled sale ($203k) by Executive VP AND CLO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $72.08 | 2,356 | $170K | 83.7% |
| 2 | $72.67 | 456 | $33K | 16.3% |
| Total | $72.18 avg | 2,812 | $203K | 100% |
| Filing → |
| PTCT | SELL | 2026-07-08 | $432K | — | Filing → |
| PTCT | SELL | 2026-06-22 | $823K | — | Filing → |
| PTCT | SELL | 2026-05-12 | $280K | — | Filing → |